Articles
  

Study of KIR Expression and HLA Ligands in CD56+ Lymphocytes of Drug Resistant Tuberculosis Patients

Abstract

Analysis of  receptor–ligand  interactions  in  the  context  of  diseases  necessitates  to understand how HLA–KIR genotypes function in diseases. Although CD56+  lymphocytes are derived from multiple lineages, they share a functional association with immunosurviellance and antimicrobial responses.
The present study aimed to determine whether KIR phenotype in CD56 lymphocytes and corresponding  HLA-class 1 ligands are associated with multidrug resistance tuberculosis (MDR-TB). We compared the frequencies of HLA-C and HLA-BW4 genes, the expression of KIRs 2DL1/2DS1, 2DL2/2DL3, 3DL1, and 2DS4 and the combinations of HLA/KIR in 32 Nifamycin and Isoniazid-resistant TB with those in 68 drug non resistant (NR) sputum smear positive pulmonary TB patients. PCR-SSP and flow cytometry were performed for HLA and KIRs typing, respectively.
We showed no significant differences between inhibitory or activating KIRs as well as HLA ligands in MDR TB patients compared with NR-TB . The combinations of inhibitory KIR-HLA ligands in MDR-TB were much more prevalent, but not statistically significant than in NR patients (p=0.07). The frequency of MDR patients with all HLA-C and HLA- BW4 ligands was higher  than  NR-TB  (p<0.009). Conversely, the  percentage  of  MDR patients having only one kind of HLA gene was significantly lower than NR-TB (p<0.01). We conclude that the expression of inhibitory KIRs with corresponding HLA ligands genes, and/or co-existence of three HLA class 1 ligands for inhibitory KIRs may be associated with drug resistance in pulmonary tuberculosis.

  1. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367:938-940.
  2. World Health Organization. Antituberculosis drug resistance in the world: the WHO/IUATLD Global project on antituberculosis drug resistance surveillance,1994–1997. WHO Global Tuberculosis Program, Geneva, Switzerland; Report No: WHO/TB/1997;229.
  3. Sutherland JS, Jeffries DJ, Donkor S, Walther B, Hill PC, Adetifa IM, et al. High ranulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting. Tuberculosis (Edinb) 2009; 89(6):398-404.
  4. Terán-Escandón D, Terán-Ortiz L, Camarena-Olvera A, González-Avila G, Vaca-Marín MA, Granados J, et al. Human leukocyte antigen associated susceptibility to pulmonary tuberculosis. Molecular analysis of class II alleles by DNA amplification and oligonucleotide hybridization in Mexican patients. Chest 1999;115(2):428–33.
  5. Dubaniewicz, A, Lewko, B, Moszkowska, G, Zamorska, B, Stepinski J. Molecular subtypes of the HLA-DR antigens in pulmonary tuberculosis. Int J Infect Dis 2000;4(3): 129–33.
  6. Rahmajothi V, Pitchappan RM, Kakkanaiah VN, Sashidhar M, Rajaram K, Ramu S, et al. Association of pulmonary tuberculosis and HLA in South India. Tubercle 1991; 72(2):123–32.
  7. Mahmoudzadeh-N H, Khalili G, Fadavi P. Allelic Distribution of Human Leukocyte Antigen in Iranian Patients With Pulmonary Tuberculosis. Hum Immunol 2003; 64(1):124–9.
  8. Mousavi T, Farnia P, Tajik N, Soofi M. A comparative study on leukocytes and subsets of CD56/CD16 lymphocytes in MDR pulmonary tuberculosis. Iran J Immunol 2010; 7(1):49-56.
  9. Park M, Song E, Park H, Kwon S, Han S, Shim Y.HLADRB1and DQB1 gene polymorphism is associated with multidrug resistant tuberculosis in Korean patients. Hum Immunol 2002; 63:S33.
  10. Sharma SK, Turaga KK, Turaga A, Balamurugan PK, Saha RM, Pandey NK, et al. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infect Genet Evol 2003; 3(3):183–8.
  11. Moretta A, Sivori S, Vitali M, Pende D, Morelli L, Augugliaro R, et al. Existence of both inhibitory (p58) and activating (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995; 182(3):875-84.
  12. Martin Am, Freitas EM, Witt CS, Christiansen FT. The genomic organization and evolution of the natural killer immunoglobulin- like receptor (KIR) gene cluster. Immunogenetics 2000; 51(4-5):268-80.
  13. Selvakumar A, Steffens U, Dupont B. Polymorphism and domain variability of human killer cell inhibitory receptors. Immunol.Rev 1997; 155:183-96.
  14. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev 2006; 214:186–201.
  15. Passweg JR, Koehl U, Uharek L, Meyer-Monard S, Tichelli A. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2006; 19(4):811-24.
  16. Azuz-Lieberman N, Markel G, Mizrahi S, Gazit R, Hanna J, Achdout H, et al. The involvement of NK cells in ankylosing spondylitis. Int Immunol 2005; 17(7):837-45.
  17. Stenger S, Rosat JP, Bloom BR, Krensky AM, Modlin RL. Granulysin: a lethal weapon of cytolytic T cells, Immunol Today 1999; 20(9):390–4.
  18. Denis M. Interleukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterium tuberculosis-infected human monocytes, Cell Immunol 1994; 156(2):529–36.
  19. Lamichhane G, Bishai W. Defining the ‘survivasome’ of Mycobacterium tuberculosis. Nat Med 2007; 13(3):280-2.
  20. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, et al. Unique subpopulations of CD56 + Nk and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001; 66(11):6477-82.
  21. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ1969; 41(1):21-43.
  22. Me´ndez1 A, Granda H, Meenagh A, Contreras1 S, Zavaleta R, Mendoza1 MF, et al. Study of KIR genes in tuberculosis patients. Tissue Antigens 2006; 68(5):386–9.
  23. Katz G, Gazit R, Arnon TI, Gonen-Gross T, Tarcic G, Markel G, et al. MHC Class I-Independent Recognition of NK-Activating Receptor KIR2DS41. J Immunol 2004; 173(3):1819–25.
  24. Mousavi T, Poormoghim H, Moradi M, Tajik N, Sahsavar F, Asadifar B. Inhibitory Killer Cell Immunoglobulin-Like Receptor KIR3DL1 in combination with HLA-B Bw4 iso is Associated with Ankylosing Spondylitis. Iran J Immunol 2010; 7(2):88-95.
  25. Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, et al. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 2010;71(10):976-81.
  26. Méndez A, Granda H, Meenagh A, Contreras S, Zavaleta R, Mendoza MF, et al. Study of KIR genes in tuberculosis patients. Tissue antigens 2006; 68(5):386-9.
  27. Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010; 115(6):1166-74.
  28. Cognet C, Farnarier C, Gauthier L, Frassati C, André P,Magérus-Chatinet A, et al. Expression of the HLA-C2- specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells. Clin Immunol 2010; 135(1):26-32.
  29. Schönberg K, Sribar M, Enczmann J, Fischer JC, Uhrberg M. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand- instructed model of NK cell receptor aquisition. Blood 2011; 117(1):98-107.
  30. Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease .J Exp Med 2005; 201(7):1025–9.
  31. Bao XJ, Hou LH, Sun AN, Qiu QC, Yuan XN, Chen MH,et al. The impact of KIR2DS4 alleles and the expression of KIR in the development of acute GVHD after unrelated allogeneic hematopoietic SCT. Bone marrow transplant 2010; 45(9):1435-41.
  32. Carrozzo M, Elia A, Mereu V, Dametto E, Fasano M, Broccoletti R, et al. HLA-C/KIR genotypes in oral lichen planus patients infected or non-infected with hepatitis C virus. Oral Disease 2011; 17(3):309-13.
  33. Sivori S, Falco M, Moretta L, Moretta A. Extending killer Ig-like receptor function: from HLA class I recognition to sensors of microbial products. Trends immunol 2010;31(8):289-94.

Files
IssueVol 10, No 3 (2011) QRcode
SectionArticles
Keywords
Human Leukocyte Antigen Killer Cell Immunoglobulin Like Receptor MDR-TB Tuberculosis
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Mousavi T, Farnia P, Tajik N, Soofi M, shahsavar F. Study of KIR Expression and HLA Ligands in CD56+ Lymphocytes of Drug Resistant Tuberculosis Patients. Iran J Allergy Asthma Immunol. 1;10(3):189-194.